Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Tackling AMR: OECD Says Greater Investment Needed In Later-Stage Drug R&D

Executive Summary

Governments should increase financial resources for novel antimicrobial drug candidates in the later stages of development and tackle shortages of existing, underused antibiotics to combat antimicrobial resistance, says a new report from the OECD.

You may also be interested in...

UK SMEs Can Help Restock The AMR Toolbox, But Only If The ‘Broken Market’ Is Fixed

The UK must build greater capacity and offer funding to support small but “highly innovative” biotechs, which are instrumental in developing solutions to combat antimicrobial resistance, the chief executive of Scotland’s NovaBiotics argues.

Panel Tells Canadian Govt A Subscription-Style Pull Incentive Is Needed To Tackle AMR

An expert panel formed by the Council of Canadian Academies says drug developers that provide “novel, valuable antibiotic solutions” should be rewarded with a “fair and reasonable guaranteed revenue” for their drugs.

Antimicrobial Exclusivity Vouchers ‘The Only Way To Go’

“If you don’t like it, come up with a better solution,” proponents of the transferable exclusivity voucher scheme said at a webinar on tackling antimicrobial resistance.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts